CytoMed Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
CytoMed Therapeutics Free Cash Flow (FCF) History (GDTC)
CytoMed Therapeutics reported −$4.3M in free cash flow for fiscal 2025, a decrease of $225,159 from the previous fiscal year, with a free cash flow margin of −1336.46%.
View full CytoMed Therapeutics company overviewCytoMed Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$4.3M | −$225,159 | — | −1336.46% |
| 2024 | 2024-12-31 | −$4.1M | −$520,663 | — | −5913.81% |
| 2023 | 2023-12-31 | −$3.6M | −$1.7M | — | — |
| 2022 | 2022-12-31 | −$1.9M | $423,135 | — | — |
| 2021 | 2021-12-31 | −$2.3M | −$1.2M | — | — |
| 2020 | 2020-12-31 | −$1.1M | — | — | — |
CytoMed Therapeutics quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
CytoMed Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$1.1M to −$4.3M, a net decrease of $3.2M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review CytoMed Therapeutics filings at SEC.gov ↗